Parkinson's disease: Autoimmunity and neuroinflammation

Autoimmunity Reviews

Volumn 15, Issue 10, 2016, Pages 1005-1011

  De Virgilio, Armando ^a   Greco, Antonio ^a   Fabbrini, Giovanni ^a   Inghilleri, Maurizio ^a   Rizzo, Maria Ida ^a   Gallo, Andrea ^a   Conte, Michela ^a   Rosato, Chiara ^a   Ciniglio Appiani, Mario ^a   de Vincentiis, Marco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autoimmunity; Inflammation; Lewy bodies; Neurodegenerative disease; Olfactory dysfunction; Parkinson; Synuclein

Indexed keywords

ANTIPARKINSON AGENT;

AUTOIMMUNITY; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; REVIEW; ANIMAL; BRAIN; DISEASE COURSE; IMMUNOLOGY; INFLAMMATION; NERVE CELL; PATHOLOGY;

ANIMALS; AUTOIMMUNITY; BRAIN; DISEASE PROGRESSION; HUMANS; INFLAMMATION; NEURONS; PARKINSON DISEASE;

EID: 84990223399     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.07.022     Document Type: Review

References (68)

1. [1] Parkinson, J., An essay on the shaking palsy. Whittingham and Rowland for Sherwood. 1817, Needly and Jones, London.
2. [2] Sylvius de la Boë, F., Opera Medica. Danielem Elsevirium et Abrahamum Wolfgang, Amsterdam, 1680.
3. [3] Tyler, K., A history of Parkinson's disease. WC, K., (eds.) Handbook of Parkinson's disease, 1992, Marcel Dekker, New York, 1–34.
4. [4] Manyam, B.V., Sánchez-Ramos, J.R., Traditional and complementary therapies in Parkinson's disease. Adv Neurol 80 (1999), 565–574.
5. [5] Zhang, Z.-X., Dong, Z.-H., GC, R.'´n., Early descriptions of Parkinson's disease in ancient China. Arch Neurol 63 (2006), 782–784.
6. [6] Charcot, J.-M., On Parkinson's disease. Lectures on diseases of the nervous system delivered at the Salpêtrière, 1877, New Sydenham Society, London, 129–156.
7. [7] Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., Kieburtz, K., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68 (2007), 384–386.
8. [8] Alzheimer's Association, 2014 Alzheimer's disease facts and figures. Alzheimers Dement 10 (2014), e47–e92.
9. [9] Van Den Eeden, S.K., Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157 (2003), 1015–1022.
10. [10] De Lau, L.M.L., Breteler, M.M.B., Epidemiology of Parkinson's disease. Lancet Neurol 5 (2006), 525–535.
11. [11] Driver, J.A., Logroscino, G., Gaziano, J.M., Kurth, T., Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72 (2009), 432–438.
12. [12] Pringsheim, T., Jette, N., Frolkis, A., Steeves, T.D.L., The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 29 (2014), 1583–1590.
13. [13] Lesage, S., Brice, A., Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18 (2009), R48–R59.
14. [14] Rosner, S., Giladi, N., Orr-Urtreger, A., Advances in the genetics of Parkinson's disease. Acta Pharmacol Sin 29 (2008), 21–34.
15. [15] Noyce, A.J., Bestwick, J.P., Silveira-Moriyama, L., Hawkes, C.H., Giovannoni, G., Lees, A.J., et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 72 (2012), 893–901.
16. [16] Benkler, M., Agmon-Levin, N., Shoenfeld, Y., Parkinson's disease, autoimmunity, and olfaction. Int J Neurosci 119 (2009), 2133–2143.
17. [17] Møller, A., Perrild, H., Pedersen, H., Høier-Madsen, M., Parkinson's disease and autoimmunity. Acta Neurol Scand 79 (1989), 173–175.
18. [18] Liu, B., Gao, H.M., Hong, J.S., Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injury: role of neuroinflammation. Environ Health Perspect 111 (2003), 1065–1073.
19. [19] Fiszer, U., Mix, E., Fredrikson, S., Kostulas, V., Olsson, T., Link, H., Gamma delta + T cells are increased in patients with Parkinson's disease. J Neurol Sci 121 (1994), 39–45.
20. [20] Benkler, M., Agmon-Levin, N., Hassin-Baer, S., Cohen, O.S., Ortega-Hernandez, O.D., Levy, A., et al. Immunology, autoimmunity, and autoantibodies in Parkinson's disease. Clin Rev Allergy Immunol 42 (2012), 164–171.
21. [21] Double, K.L., Rowe, D.B., Carew-Jones, F.M., Hayes, M., Chan, D.K., Blackie, J., et al. Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol 217 (2009), 297–301.
22. [22] Papachroni, K.K., Ninkina, N., Papapanagiotou, A., Hadjigeorgiou, G.M., Xiromerisiou, G., Papadimitriou, A., et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 101 (2007), 749–756.
23. [23] Yanamandra, K., Gruden, M.A., Casaite, V., Meskys, R., Forsgren, L., Morozova-Roche, L.A., Alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One, 6, 2011, e18513.
24. [24] Zappia, M., Crescibene, L., Bosco, D., Arabia, G., Nicoletti, G., Bagala, A., et al. Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol Scand 106 (2002), 54–57.
25. [25] Orr, C.F., Rowe, D.B., Mizuno, Y., Mori, H., Halliday, G.M., A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128 (2005), 2665–2674.
26. [26] Graham, D.G., On the origin and significance of neuromelanin. Arch Pathol Lab Med 103 (1979), 359–362.
27. [27] Oberlander, U., Pletinckx, K., Dohler, A., Muller, N., Lutz, M.B., Arzberger, T., et al. Neuromelanin is an immune stimulator for dendritic cells in vitro. BMC Neurosci, 12, 2011, 116.
28. [28] Koutsilieri, E., Lutz, M.B., Scheller, C., Autoimmunity, dendritic cells and relevance for Parkinson's disease. J Neural Transm 120 (2013), 75–81.
29. [29] Wilms, H., Rosenstiel, P., Sievers, J., Deuschl, G., Zecca, L., Lucius, R., Activation of microglia by human neuromelanin is NFkappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 17 (2003), 500–502.
30. [30] Zhang, W., Phillips, K., Wielgus, A.R., Liu, J., Albertini, A., Zucca, F.A., et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 19 (2011), 63–72.
31. [31] Carvey, P.M., McRae, A., Lint, T.F., Ptak, L.R., Lo, E.S., Goetz, C.G., et al. The potential use of dopamine neuron antibody and a striatal-derived neurotropic factor as diagnostic markers in Parkinson's disease. Neurology 41 (1991), 53–58.
32. [32] Le, W.D., Rowe, D.B., Jankovic, J., Xei, W., Apple, S.H., Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol 56 (1999), 194–200.
33. [33] Chen, S., Le, W.D., Xie, W.J., Alexianu, M.E., Engelhardt, J.I., Siklos, L., et al. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 55 (1998), 1075–1080.
34. [34] He, Y., Le, W.D., Appel, S.H., Role of FCγ receptors in nigral cell injury induced by Parkinson's disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 176 (2002), 322–327.
35. [35] Abramsky, O., Litvin, Y., Autoimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia. Perspect Biol Med, 22, 1978, 104114.
36. [36] Luedtke, R.R., Griffin, S.A., Conroy, S.S., Jin, X., Pinto, A., Sesack, S.R., Immunoblot and immunohistochemical comparison of murine monoclonal antibodies specific for the rat D1a and D1b dopamine receptor subtypes. J Neuroimmunol 101 (1999), 170–187.
37. [37] Myers, P.R., Donlon, M., McCarthy, K., Livengood, D., Shain, W., Evidence for a dopamine receptor antibody. Biochem Biophys Res Commun 72 (1976), 1311–1318.
38. [38] Farooqui, S.M., Brock, J.W., Hamdi, A., Prasad, C., Antibodies against synthetic peptides predicted from the nucleotide sequence of D2 receptor recognize native dopamine receptor protein in rat striatum. J Neurochem 57 (1991), 1363–1369.
39. [39] Gibb, W.R., Lees, A.J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 (1988), 745–752.
40. [40] Postuma, R.B., Aarsland, D., Barone, P., Burn, D.J., Hawkes, C.H., Oertel, W., et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 27 (2012), 617–626.
41. [41] Hely, M.A., Morris, J.G.L., Reid, W.G.J., Trafficante, R., Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20 (2005), 190–199.
42. [42] Hely, M.A., Reid, W.G.J., Adena, M.A., Halliday, G.M., Morris, J.G.L., The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 23 (2008), 837–844.
43. [43] Lerler, A., Bagic, A., Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov Disord 23 (2008), 1076–1084.
44. [44] Goedert, M., Spillantini, M.G., Del Tredici, K., Braak, H., 100 years of Lewy pathology. Nat Rev Neurol 9 (2012), 13–24.
45. [45] Iwanaga, K., Wakabayashi, K., Yoshimoto, M., Tomita, I., Satoh, H., Takashima, H., et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 52 (1999), 1269–1271.
46. [46] Goetz, C.G., The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med, 1, 2011, a008862.
47. [47] Popat, R.A., Van Den Eeden, S.K., Tanner, C.M., Kamel, F., Umbach, D.M., Marder, K., et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur J Neurol 18 (2011), 756–765.
48. [48] Hong, Z., Shi, M., Chung, K.A., Quinn, J.F., Peskind, E.R., Galasko, D., et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133 (2010), 713–726.
49. [49] Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 9 (2013), 131–140.
50. [50] Brooks, D.J., Pavese, N., Imaging biomarkers in Parkinson's disease. Prog Neurobiol 95 (2011), 614–628.
51. [51] Lehericy, S., Sharman, M.A., Santos, C.L.D., Paquin, R., Gallea, C., Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord 27 (2012), 822–830.
52. [52] Lehericy, S., Bardinet, E., Poupon, C., Vidailhet, M., Francois, C., 7 tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Mov Disord 29 (2014), 1574–1581.
53. [53] Coelho, M., Ferreira, J.J., Late-stage Parkinson disease. Nat Rev Neurol 8 (2012), 435–442.
54. [54] Fox, S.H., Katzenschlager, R., Lim, S.Y., Ravina, B., Seppi, K., Coelho, M., et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 26 (2011), S2–41.
55. [55] Connolly, B., Lang, A.E., Pharmacological treatment of Parkinson's disease: a review. JAMA 311 (2014), 1670–1683.
56. [56] Ton, T.G., Heckbert, S.R., Longstreth, W.T. Jr., Rossing, M.A., Kukull, W.A., Franklin, G.M., et al. Non steroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 21 (2006), 964–969.
57. [57] Plane, J.M., Shen, Y., Pleasure, D.E., Deng, W., Prospects for minocycline neuroprotection. Arch Neurol 67 (2010), 1442–1448.
58. [58] Ravina, B., A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66 (2006), 664–671.
59. [59] Thevenet, J., Pescini Gobert, R., van Huijsduijnen R, H., Wiessner, C., YJ, S., Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One, 6, 2011, e21519.
60. [60] Moehle, M.S., Webber, P.J., Tse, T., Sukar, N., Standaert, D.G., DeSilva, T.M., et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32 (2012), 1602–1611.
61. [61] Wenz, T., PGC-1α activation as a therapeutic approach in mitochondrial disease. IUBMB Life 61 (2009), 1051–1062.
62. [62] Hondares, E., Pineda-Torra, I., Iglesias, R., Staels, B., Villarroya, F., Giralt, M., PPARδ, but not PPARα, activates PGC-1α gene transcription in muscle. Biochem Biophys Res Commun 354 (2007), 1021–1027.
63. [63] Pardo, R., Enguix, N., Lasheras, J., Feliu, J.E., Kralli, A., Villena, J.A., Rosiglitazone-induced mitochondrial biogenesis in white adipose tissue is independent of peroxisome proliferator- activated receptor γ coactivator-1α. PLoS One, 6, 2011, e26989.
64. [64] Suwa, M., Egashira, T., Nakano, H., Sasaki, H., Kumagai, S., Metformin increases the PGC-1α protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J Appl Physiol 101 (2006), 1685–1692.
65. [65] Chowanadisai, W., Bauerly, K.A., Tchaparian, E., Wong, A., Cortopassi, G.A., Rucker, R.B., Pyrroloquinoline quinine stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1α expression. J Biol Chem 285 (2010), 142–152.
66. [66] Irrcher, I., Ljubicic, V., Kirwan, A.F., Hood, D.A., AMP activated protein kinase-regulated activation of the PGC-1alpha promoter in skeletal muscle cells. PLoS One, 3, 2008, e3614.
67. [67] Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 (2006), 1109–1122.
68. [68] Shoenfeld, Y., Blank, M., Abu-Shakra, M., Amital, H., Barzilai, O., Berkun, Y., et al. The mosaic of autoimmunity: prediction, autoantibodies and therapy in autoimmune disease. IMAJ 10 (2008), 13–19.